|
|
Post by Chris-C on Mar 18, 2021 10:11:01 GMT -5
Much respect ...if that is the case, a lot of respect just for admitting that they didn’t get it right in the first place. ❤️ Which is the first step to fixing it. Good Grief - we have been telling Mike this since the first time I ever met the guy and I am sure Bill has too. Back in the day Mike was the chief marketing guy. Calling the cartridges "units" was IMO the biggest marketing blunder Al Mann ever made and IMO has retarded adoption. I understand Al was trying to address the Exubera dosing mess and thought calling them "units" would make things simple but instead it resulted in doctors trying tp compare afrezza to the RAAs and it has resulted in dose conversions and stacking fears and all the rest. If the cartridges are relabeled to small, medium and large it would provide a new paradigm for dosing and concerns about second and even third dosing should be eliminated as the doctors will no longer try to compare to RAAs.Gen sayhey24 I tend to agree. This brings up a marketing question I have wondered about since becoming a shareholder over a decade ago. Disclaimer: Marketing is not my area of expertise, and a I know that a little knowledge is often a dangerous thing. But I have been involved in focus group work. Sometimes I am puzzled because it seems that the company, having invested billions into R&D, has (in the past) not taken the time to actually understand its target populations: Patients and providers in the real world.It seems to me that before a decision is made about packaging, dosing and prescribing, a company would invest $$$ to get as clear a picture as possible of how best to inform those who prescribe and use Afrezza, from every possible aspect. With a better understanding of people, constraints and contexts, many missteps can be avoided, money can be saved, and faster progress can be made. I cannot help but believe that some of the decisions that have been made in the past were not sufficiently informed and the result was not only problematic from a financial standpoint but also from the critical standpoint of failed experiences and a damaged company reputation (brand). Trial and error learning tends to be expensive and can be disastrous to startup companies, even those started by entrepreneurs with deep pockets. I never met Al Mann but have deep respect for him. Yet, these questions make me wonder if some of those he employed served him poorly by telling him only what he wanted to hear rather than what he needed to hear? |
|
|
|
Post by geomean on Mar 18, 2021 11:22:53 GMT -5
|
|
|
|
Post by boca1girl on Mar 18, 2021 12:04:55 GMT -5
I think the translation just got it wrong and Peach should have been Pedes. |
|
|
|
Post by sayhey24 on Mar 18, 2021 14:33:33 GMT -5
Good Grief - we have been telling Mike this since the first time I ever met the guy and I am sure Bill has too. Back in the day Mike was the chief marketing guy. Calling the cartridges "units" was IMO the biggest marketing blunder Al Mann ever made and IMO has retarded adoption. I understand Al was trying to address the Exubera dosing mess and thought calling them "units" would make things simple but instead it resulted in doctors trying tp compare afrezza to the RAAs and it has resulted in dose conversions and stacking fears and all the rest. If the cartridges are relabeled to small, medium and large it would provide a new paradigm for dosing and concerns about second and even third dosing should be eliminated as the doctors will no longer try to compare to RAAs.Gen sayhey24 I tend to agree. This brings up a marketing question I have wondered about since becoming a shareholder over a decade ago. Disclaimer: Marketing is not my area of expertise, and a I know that a little knowledge is often a dangerous thing. But I have been involved in focus group work. Sometimes I am puzzled because it seems that the company, having invested billions into R&D, has (in the past) not taken the time to actually understand its target populations: Patients and providers in the real world.It seems to me that before a decision is made about packaging, dosing and prescribing, a company would invest $$$ to get as clear a picture as possible of how best to inform those who prescribe and use Afrezza, from every possible aspect. With a better understanding of people, constraints and contexts, many missteps can be avoided, money can be saved, and faster progress can be made. I cannot help but believe that some of the decisions that have been made in the past were not sufficiently informed and the result was not only problematic from a financial standpoint but also from the critical standpoint of failed experiences and a damaged company reputation (brand). Trial and error learning tends to be expensive and can be disastrous to startup companies, even those started by entrepreneurs with deep pockets. I never met Al Mann but have deep respect for him. Yet, these questions make me wonder if some of those he employed served him poorly by telling him only what he wanted to hear rather than what he needed to hear? Well, many many companies spent lots of good money with marketing experts and still come up with bonehead results. Heck, some even come up with flying hamburger diabetes commercials. Al Mann was trying to address the issues with Exubera and a huge one was complex dosing and he thought by calling the cartridges units it would solve the problem. It seemed like a good idea at the time. The unintended consequence was the entire diabetes community viewed afrezza as another RAA and directly compared the two which included dosing. From day one second dosing of afrezza should have been promoted as a benefit. Instead we have had the mashing of teeth and have been told its a huge negative. How often are the same guys who say we need a faster insulin telling us afrezza is too fast and sometimes needs a second dose which they say is bad. That crew the other week who had the panel discussion on needing a faster insulin brought up second dosing of afrezza as a negative until they got hit with some questions challenging them. How many discussions have there been just on this board with guys like Aged Hippie who would actively contend how bad second dosing is. Without doubt Sanofi's involvement in the initial rollout made things worse and did serve Al and MNKD poorly. Up until now Mike has not had the money to change the label. Now the ball is in his court. Lets see what he does. |
|
